Tarsus Pharmaceuticals, Inc. reports developments tied to its commercial eye-care franchise and biopharmaceutical pipeline. Company news commonly covers XDEMVY, its lotilaner ophthalmic solution marketed in the U.S. for Demodex blepharitis, including product-sales updates, prescribing trends, conference presentations, and international regulatory milestones for TP-03 through its Greater China partner.
Updates also address pipeline programs such as TP-04 for ocular rosacea and TP-05, an investigational oral lotilaner tablet being studied for Lyme disease prevention. Recurring corporate items include quarterly and annual financial results, investor-conference participation, board and governance changes, and business updates related to Tarsus' ophthalmology-focused commercialization strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.